658084-23-2 | SU11274

Chemical type

• Selective c-Met inhibitor

^[1]

• Small molecule inhibitor of c-Met (hepatocyte growth factor receptor)
• ATP-competitive tyrosine kinase inhibitor

^[2]

Key properties

• Inhibits c-Met phosphorylation
• Reduces viability and migration in cancer cells

^[1]

• Inhibits HGF-dependent signaling and phosphorylation of c-Met
• Induces autophagy via increased LC3-I to LC3-II conversion and Beclin-1 upregulation
• Causes time- and dose-dependent cell growth inhibition, G1 cell cycle arrest, and autophagic cell death
• Activates ERK and p53 pathways, leading to Bcl-2 phosphorylation
• Effective at low nanomolar concentrations (e.g., 100 nM for autophagy induction in A549 cells)

^[2]

• Suppresses growth of colorectal carcinoma, lung, breast, and liver cancer models
• Used in preclinical studies

^[1]

• Therapeutic agent for non-small-cell lung cancer (NSCLC) treatment
• Inhibitor of aberrant c-Met expression in cancers
• Research tool to study autophagy and apoptosis in tumor cells

^[2]

Classification by use

• Chemicals used in targeted cancer therapy
• Tyrosine kinase inhibitors

^[1]

• Chemicals used as kinase inhibitors
• Chemicals used in cancer therapy and autophagy induction

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] PHA-665752’s Antigrowth and Proapoptotic Effects on HSC-3 Human Oral Cancer Cells, Int. J. Mol. Sci., 2024, 25(5), 2871
2. [Cite:2] Activation of ERK–p53 and ERK-Mediated Phosphorylation of Bcl-2 Are Involved in Autophagic Cell Death Induced by the c-Met Inhibitor SU11274 in Human Lung Cancer A549 Cells, Journal of Pharmacological Sciences, Volume 118, Issue 4, 2012, Pages 423-432